Profiling Of Lung Cancer
Image Source: biotech-weblog.com
Researchers from the Duke University Comprehensive Cancer Center found a new study to be able to predict which tumors would be most likely to respond to traditional therapy or standard first line therapy administration of what is called platinum-based chemotherapy, which works by damaging DNA and interrupting the chain of cellular events that leads to cancer proliferation. The genetic profile of a particular lung tumor can help clinicians make the crucial decision about which treatment to try first. They were able to draw conclusions about which genes were turned on and which were turned off in these samples, and subsequently created a genomic map for cisplatin sensitivity a most commomly used agent in lung cancer treatment.
Most of these patients gain the most benefit from their initial treatment strategy. It could also make a huge difference in the treatment of patients with late-stage lung cancer. This represents a big step in the move toward individualized medicine.